Skip to main content
MD
NYSE Industrial Applications And Services

Shareholders Approve 8 Million New Shares for Incentive Plan, Signaling Potential Dilution

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$22.93
Mkt Cap
$1.883B
52W Low
$11.84
52W High
$24.99
Market data snapshot near publication time

summarizeSummary

Pediatrix Medical Group shareholders approved an amendment to its incentive compensation plan, authorizing an additional 8 million shares for future issuance, representing significant potential dilution.


check_boxKey Events

  • Incentive Plan Expanded

    Shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, increasing the number of shares available for issuance under the plan by 8,000,000 shares. This represents a potential dilution of approximately 9.63% of current outstanding shares.

  • Board of Directors Elected

    All nominated directors were elected to serve until the 2027 Annual Shareholders' Meeting. Notably, director John M. Starcher, Jr. received 25,909,618 'Against' votes, representing approximately 35.8% of the total votes cast for his election.

  • Auditor Ratified

    The appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the 2026 fiscal year was ratified by shareholders.

  • Executive Compensation Approved

    Shareholders approved, on a non-binding, advisory basis, the compensation of the company's named executive officers for the 2025 fiscal year.


auto_awesomeAnalysis

Pediatrix Medical Group shareholders approved an amendment to its 2008 Incentive Compensation Plan, authorizing an additional 8,000,000 shares for future issuance. This represents a potential dilution of approximately 9.63% based on the current outstanding shares, which is a significant amount and could create an overhang on the stock. While the approval of an incentive plan is common, the magnitude of authorized shares is notable. Additionally, all nominated directors were elected at the Annual Meeting, though John M. Starcher, Jr. received a substantial 35.8% of votes against his election, indicating some shareholder dissent. The ratification of auditors and advisory approval of executive compensation are routine annual meeting matters.

At the time of this filing, MD was trading at $22.93 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.84 to $24.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MD - Latest Insights

MD
May 07, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
MD
May 05, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
MD
May 05, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
7
MD
May 05, 2026, 6:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
MD
Mar 27, 2026, 6:50 AM EDT
Filing Type: DEF 14A
Importance Score:
8
MD
Mar 26, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
7
MD
Feb 19, 2026, 7:00 AM EST
Filing Type: 10-K
Importance Score:
9
MD
Feb 19, 2026, 6:50 AM EST
Filing Type: 8-K
Importance Score:
8